AMP Amphion Innovations Plc

RNS Number:1784Z
Amphion Innovations PLC
02 March 2006




                            Amphion Innovations PLC

                       Partner Company Motif BioSciences

  Announces Completion of $1.875 Million Financing and Commencement of Arabian
                             Gulf Sampling Program



02 March 2006 - Amphion Innovations plc's (Amphion) partner company Motif
BioSciences (Motif), a population genetics company focused on the discovery of
genes causing common diseases by utilising human genetic data from the Persian/
Arabian Gulf region, announces that it has completed a $1.875 million financing,
and has received and begun analysing the first sets of human genetic samples
from the Arabian Gulf.



Amphion, the lead investor in this round, previously announced its $500,000
investment on 3 January 2006, and holds a 47.22% stake in the Company. The
financing, which was oversubscribed, has since completed with a combination of
new and existing investors.  The additional investment will support Motif's
sample collection and sample analysis programs in the Persian/Arabian Gulf, a
program now well underway with the recent acquisition and analysis of two sets
of genetic data from the region.



To support the Company's growing research and collaborative efforts, Motif has
hired Kevin Arnold, formerly the Executive Director of Operations of Genaissance
Pharmaceuticals, to serve as Executive Director of Genomic Operations at Motif.
Manish Pungliya, formerly Bioinformatics Scientist at Genaissance
Pharmaceuticals, has been hired to lead Motif's bioinformatics effort.



Richard C.E. Morgan, CEO of Amphion and Chairman of the Board of Motif, said:

"We are delighted to be moving forward with our programmes in the Gulf. Motif
promises to bring understanding of the genetic component of a variety of medical
afflictions in the region, ranging from rare disorders to ones, like diabetes,
that are of interest to people around the world.  This understanding can lead to
better diagnosis and, hopefully, innovative therapeutic strategies to help those
afflicted in the region and elsewhere."



Stephen Cass, Chief Executive Officer of Motif, said:

"The strong support of our existing investors, as well as the addition of
important new investors from the Gulf, is a great show of confidence in Motif's
strong progress.  In a region which we think holds perhaps the most promising
sources of future genetic disease discoveries, this latest round will enable us
to aggressively pursue our research and work plan in the region.  Given our
current progress in acquiring samples, raising capital, and developing
partnerships with key Gulf healthcare organizations, we believe that 2006 can be
a year of rapid growth for the Company's research program, pharma industry
interest, and shareholder value."





For More Information:


Financial Dynamics
Ben Atwell / John Gilbert                                +44 (0) 20 7831 3113

Amphion Innovations
Richard Morgan, CEO                                      1 (212) 210-6224
Ben Austin, Investor Relations                           1 (212) 210-6248
baustin@amphionplc.com                                   1 (917) 686-3979 mobile


About Amphion Innovations plc

Amphion Innovations plc recently listed on the AIM Exchange in London under the
symbol AMP. Amphion's business is the formation, financing, management and
development of life science and technology companies, working in partnership
with corporations, governments, universities, and entrepreneurs seeking to
commercialize their intellectual property.

On the Web: www.amphionplc.com



About Motif BioSciences

Motif BioSciences is a population genetics company focused on discovering genes
causing common diseases by utilising human genetic data from the Persian/Arabian
Gulf region.  Motif is headquartered in the US and London, with additional
operations in the Gulf region to develop epidemiological, genealogical and
genetic information.



On the Web: www.motifbio.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCGCGDXUGGGGLD

Amphion Innovations (LSE:AMP)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024

Amphion Innovations (LSE:AMP)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024